(Q38975988)

8 September 2017

title

Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma (English)

1 reference

8 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Tijana Stanković

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jelena Dinic

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Radan Dzodic

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Zorica Milosevic

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Zorka Milovanovic

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jelena Stojsic

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Nikola Tanic

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Jasna Bankovic

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

23 June 2014

1 reference

8 September 2017

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

411-423

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

Multi-targeted approach in the treatment of thyroid cancer

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Anaplastic thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Results of combined treatment of anaplastic thyroid carcinoma (ATC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Anaplastic thyroid carcinoma: pathogenesis and emerging therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

7 January 2021

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Ras proteins in the control of the cell cycle and cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Biology of Ras in thyroid cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Specific pattern of RAS oncogene mutations in follicular thyroid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Psoriasin (S100A7) expression and invasive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Isoform-specific ras functions in development and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

A restricted spectrum of NRAS mutations causes Noonan syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Endogenous c-N-Ras provides a steady-state anti-apoptotic signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

p53 family proteins in thyroid cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

B-Raf and the inhibitors: from bench to bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

mTOR inhibitors in cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2014.06.005

10.1016/J.TRSL.2014.06.005

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25016932%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference